MedImmune Showcases Commitment to Cancer Research at Annual Meeting of the American Association for Cancer Research

GAITHERSBURG, Md., April 16 /PRNewswire/ -- MedImmune today announced that ten abstracts on progress being made in various oncology programs will be presented during the Annual Meeting of the American Association for Cancer Research in Washington, DC from April 17 to 21.

"Through innovative approaches, MedImmune strives to apply novel treatment paradigms to help extend and improve the lives of people with cancer and we are proud to share data from our increasingly broad oncology portfolio at this year's meeting," said Klaus Bosslet, vice president, oncology research

MedImmune research scheduled to be presented includes:

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC , has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com .

CONTACT: Perla Copernik, +1-301-398-4952

Web site: http://www.medimmune.com/